Silk fibroin encapsulated powder reservoirs for sustained release of adenosine.

Due to its unique properties, silk fibroin was studied as a biodegradable polymer vehicle for sustained, local delivery of the anticonvulsant adenosine from encapsulated reservoirs. Silk is a biologically derived protein polymer that is biocompatible, mechanically strong and degrades to non-toxic products in vivo. To achieve local, sustained, controlled adenosine release from fully degradable implants, solid adenosine powder reservoirs were coated with silk fibroin. Material properties of the silk coating including thickness, crystallinity and morphology were investigated to assess the relationships between silk coating biomaterial features and adenosine release from silk encapsulated reservoirs. Reservoir coating thickness was varied through manipulation of the silk coating solution concentration and number of coatings applied. Release studies were also performed in proteinase type XIV to model the effects of degradation. Increasing the barrier to diffusion, either by increasing coating thickness or crystallinity was found to delay adenosine burst, decrease average daily release rate, and increase duration of release. In the case of encapsulated reservoirs coated with eight layers of 8% (w/v) silk, a linear release profile was observed and adenosine release was sustained for 14days. The ability to achieve nearly constant release for 2weeks for adenosine via control of the silk coating suggests these encapsulated reservoirs represent a novel system for delivering adenosine. We anticipate that this approach could also be extended to other implant needs and small-molecule drugs to treat a range of clinical needs.

[1]  B. Lippold,et al.  Parameters controlling drug release from pellets coated with aqueous ethyl cellulose dispersion , 1989 .

[2]  A. Daugherty,et al.  Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres , 1997 .

[3]  D. Boison Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies , 2009, Epilepsy Research.

[4]  Kinam Park,et al.  Mechanisms of controlled drug release from drug-eluting stents. , 2006, Advanced drug delivery reviews.

[5]  D. Boison The adenosine kinase hypothesis of epileptogenesis , 2008, Progress in Neurobiology.

[6]  A. Dash,et al.  Therapeutic applications of implantable drug delivery systems. , 1998, Journal of pharmacological and toxicological methods.

[7]  A. Coombes,et al.  The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. , 1999, Vaccine.

[8]  T. Higuchi MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.

[9]  N. Peppas,et al.  Present and future applications of biomaterials in controlled drug delivery systems. , 1981, Biomaterials.

[10]  Ung-Jin Kim,et al.  Structure and properties of silk hydrogels. , 2004, Biomacromolecules.

[11]  Mingzhong Li,et al.  Enzymatic degradation behavior of porous silk fibroin sheets. , 2003, Biomaterials.

[12]  G. Kidder Adenosine kinase from , 1982 .

[13]  G. Vunjak‐Novakovic,et al.  Silk fibroin as an organic polymer for controlled drug delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[14]  T. Asakura,et al.  Solvent- and mechanical-treatment-induced conformational transition of silk fibroins studies by high-resolution solid-state carbon-13 NMR spectroscopy , 1990 .

[15]  H. Rupprecht,et al.  Film coating of pellets with insoluble polymers obtained in situ crosslinking in the fluidized bed , 1993 .

[16]  D. Kaplan,et al.  In vivo degradation of three-dimensional silk fibroin scaffolds. , 2008, Biomaterials.

[17]  H. Brem,et al.  Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. , 2005, Anticancer research.

[18]  T. Dunwiddie,et al.  Adenosine and suppression of seizures. , 1999, Advances in neurology.

[19]  I. Tucker,et al.  Matrix formation in sustained release tablets: possible mechanism of dose dumping. , 2003, International journal of pharmaceutics.

[20]  J. Siepmann,et al.  How to adjust desired drug release patterns from ethylcellulose-coated dosage forms. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[21]  A. Sollevi,et al.  Experimental pain by ischaemic contractions compared with pain by intramuscular infusions of adenosine and hypertonic saline , 2003, European journal of pain.

[22]  J. Siepmann,et al.  Polymer blends for controlled release coatings. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[23]  D. Kaplan,et al.  Silk microspheres for encapsulation and controlled release. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[24]  T. Dahl,et al.  Mechanisms to Control Drug Release from Pellets Coated with a Silicone Elastomer Aqueous Dispersion , 1992, Pharmaceutical Research.

[25]  A Deutch,et al.  Controlled release of dopamine from a polymeric brain implant: In vivo characterization , 1989, Annals of neurology.

[26]  J. McPherson,et al.  The human immune response to reconstituted bovine collagen. , 1986, Journal of immunology.

[27]  Nicholas A. Peppas,et al.  A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs , 1987 .

[28]  David L Kaplan,et al.  In vitro evaluation of electrospun silk fibroin scaffolds for vascular cell growth. , 2008, Biomaterials.

[29]  N. Déglon,et al.  Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Fariña,et al.  Potential applications of PLGA film-implants in modulating in vitro drugs release. , 2002, International journal of pharmaceutics.

[31]  Christopher T. Rhodes,et al.  The sustained release coating of solid dosage forms : a historical review , 1995 .

[32]  Randall J Mrsny,et al.  Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.

[33]  Robert Langer,et al.  INVITED REVIEW POLYMERIC DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE , 1980 .

[34]  J. Swarbrick,et al.  Encyclopedia of Pharmaceutical Technology , 2006 .

[35]  K. Shakesheff,et al.  Polymer carriers for drug delivery in tissue engineering. , 2007, Advanced drug delivery reviews.

[36]  S. Prasong,et al.  In vitro Degradation Behavior of Bombyx mori Silk Fibroin Films Exposure to Protease XXIII , 2009 .

[37]  Peng Xu,et al.  Biomaterial coatings by stepwise deposition of silk fibroin. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[38]  K. Shakesheff,et al.  Polymeric systems for controlled drug release. , 1999, Chemical reviews.

[39]  Jiyoung M Dang,et al.  Natural polymers for gene delivery and tissue engineering. , 2006, Advanced drug delivery reviews.

[40]  M. J. Lynch,et al.  Dissolution and compatibility considerations for the use of mannitol in solid dosage forms. , 1969, Journal of pharmaceutical sciences.

[41]  D. Boison Adenosine-Based Cell Therapy Approaches for Pharmacoresistant Epilepsies , 2007, Neurodegenerative Diseases.

[42]  David L Kaplan,et al.  Silk polymer-based adenosine release: therapeutic potential for epilepsy. , 2008, Biomaterials.

[43]  W. Mark Saltzman,et al.  New Methods for Direct Delivery of Chemotherapy for Treating Brain Tumors , 2006, The Yale journal of biology and medicine.

[44]  T. Vandamme,et al.  Controlled release of levamisole from poly-(E-caprolactone) matrices: III. Effects of molecular weight and polymer coating on drug release , 1996 .

[45]  N. de Tribolet,et al.  Preoperative silk suture embolization of cerebral and dural arteriovenous malformations. , 2001, Neurosurgical focus.

[46]  K. Fujimoto,et al.  Rat brain expresses serum calcium-decreasing factor (caldecrin) , 2002, Neuroscience Letters.

[47]  Eleanor M. Pritchard,et al.  Antiepileptic effects of silk-polymer based adenosine release in kindled rats , 2009, Experimental Neurology.

[48]  R. Simon,et al.  Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. , 2007, Brain : a journal of neurology.

[49]  David L Kaplan,et al.  In vitro degradation of silk fibroin. , 2005, Biomaterials.

[50]  R. Bodmeier,et al.  Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit) RS, ethylcellulose and shellac. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[51]  M B McCarthy,et al.  Functionalized silk-based biomaterials for bone formation. , 2001, Journal of biomedical materials research.

[52]  D. Kaplan,et al.  Effect of hydration on silk film material properties. , 2010, Macromolecular bioscience.

[53]  David L Kaplan,et al.  The inflammatory responses to silk films in vitro and in vivo. , 2005, Biomaterials.

[54]  David L Kaplan,et al.  Silk-based biomaterials. , 2003, Biomaterials.

[55]  D. Boison Adenosine kinase, epilepsy and stroke: mechanisms and therapies. , 2006, Trends in pharmacological sciences.

[56]  David L Kaplan,et al.  Nanolayer biomaterial coatings of silk fibroin for controlled release. , 2007, Journal of controlled release : official journal of the Controlled Release Society.